General pharmacology of a new analgesic-AP-237.
1-n-Butyryl-4-cinnamylpiperazine hydrochloride, AP-237, was studied in a variety of general screening tests. Several routes of administration, including oral, subcutaneous, intraperitoneal, and intra-muscular, were employed. It was compared to morphine and pentazocine in many tests. It was found to be a potent analgesic in rats and mice with better oral efficacy than the reference agents. It did not exhibit anti-inflammatory, antipyretic, or anticonvulsant activity but appeared to have some tranquilizing properties. Its general pharmacology resembles the reference agents morphine and pentazocine, but with several differences.
D000700:Analgesics / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001341:Autonomic Nervous System / Q000187:drug effects; D002087:Butyrates / Q000494:pharmacology / Q000633:toxicity; D002415:Cats; D002490:Central Nervous System / Q000187:drug effects; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D005260:Female; D006168:Guinea Pigs; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D010879:Piperazines / Q000494:pharmacology* / Q000633:toxicity; D011817:Rabbits; D051381:Rats
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D002087:Butyrates; D010879:Piperazines; C000347:1-N-butyryl-4-cinnamylpiperazine